A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Seattle Genetics

Protocol Number
SGN19A-003

To Learn More Call
201-510-0910